X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will provide GSK with access to LifeMine’s genomically enabled drug discovery platform to identify novel small molecule leads directed to up to three human targets provided by GSK addressing multiple disease areas.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Collaboration March 23, 2022
Details:
Proceeds from the financing will be used to advance LifeMine’s proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fidelity Management & Research Company
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 23, 2022
Details:
Proceeds will enable advancement and acceleration of the Company’s transformative drug discovery programs derived from digital search of the fungal biosphere to discover and develop highly impactful precision medicines.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rick Klausner
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
